Dual Angiotensin Receptor and Neprilysin Inhibitor Ameliorates Portal Hypertension in Portal Hypertensive Rats

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2020 Apr 8

PMID 32252377

Citations 5

Authors

Shao-Jung Hsu

Hui-Chun Huang

Chiao-Lin Chuang

Ching-Chih Chang

Ming-Chih Hou

Fa-Yauh Lee

Shou-Dong Lee

Affiliations

Soon will be listed here.

Abstract

Background: Portal hypertension is characterized by exaggerated activation of the renin-angiotensin-aldosterone axis. Natriuretic peptide system plays a counter-regulatory role, which is modulated by neprilysin. LCZ696 (sacubitril/valsartan) is a dual angiotensin receptor and neprilysin inhibitor. This study evaluated the effect of LCZ696 on portal hypertensive rats.

Methods: Portal hypertension was induced by partial portal vein ligation (PVL) in rats. LCZ696, valsartan (angiotensin receptor blocker), or normal saline (control) was administered in PVL rats for 10 days. Then, hemodynamic and biochemistry data were obtained. The hepatic histology and protein expressions were surveyed. On the parallel groups, the portal-systemic shunting degrees were determined.

Results: LCZ696 and valsartan reduced mean arterial pressure and systemic vascular resistance. LCZ696, but not valsartan, reduced portal pressure in portal hypertensive rats (control vs. valsartan vs. LCZ696: 15.4 ± 1.6 vs. 14.0 ± 2.3 vs. 12.0 ± 2.0 mmHg, control vs. LCZ696: < 0.05). LCZ696 and valsartan improved liver biochemistry data and reduced intrahepatic Cluster of Differentiation 68 (CD68)-stained macrophages infiltration. Hepatic endothelin-1 (ET-1) protein expression was downregulated by LCZ696. The portal-systemic shunting was not affected by LCZ696 and valsartan.

Conclusion: LCZ696 and valsartan reduced mean arterial pressure through peripheral vasodilation. Furthermore, LCZ696 significantly reduced portal pressure in PVL rats via hepatic ET-1 downregulation.

Citing Articles

Elevated serum neprilysin levels in patients with chronic hepatitis C and metabolic dysfunction-associated steatotic liver disease: hepatic oxidative stress as an underlying mechanism.

Kitsugi K, Chida T, Hanaoka T, Umemura M, Yamashita M, Ito J Mol Biol Rep. 2024; 52(1):81.

PMID: 39722039 DOI: 10.1007/s11033-024-10152-0.

The Renin-Angiotensin System in Liver Disease.

McGrath M, Wentworth B Int J Mol Sci. 2024; 25(11).

PMID: 38891995 PMC: 11172481. DOI: 10.3390/ijms25115807.

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling.

Mustafa N, Jalil J, Zainalabidin S, Saleh M, Asmadi A, Kamisah Y Front Pharmacol. 2022; 13:892460.

PMID: 36003518 PMC: 9393311. DOI: 10.3389/fphar.2022.892460.

Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias.

Sutanto H, Dobrev D, Heijman J Int J Mol Sci. 2021; 22(16).

PMID: 34445698 PMC: 8396594. DOI: 10.3390/ijms22168994.

Angiotensin II receptor Neprilysin inhibitor (LCZ696) compared to Valsartan attenuates Hepatotoxicity in STZ-induced hyperglycemic rats.

Alqahtani F, Mohany M, Alasmari A, Alanazi A, Belali O, Ahmed M Int J Med Sci. 2020; 17(18):3098-3106.

PMID: 33173431 PMC: 7646100. DOI: 10.7150/ijms.49373.

References

Almeida S, Cardoso C, Orellano L, Reis A, Barcelos L, Andrade S . Natriuretic peptide clearance receptor ligand (C-ANP4-23 ) attenuates angiogenesis in a murine sponge implant model. Clin Exp Pharmacol Physiol. 2014; 41(9):691-7. DOI: 10.1111/1440-1681.12251. View

Shah V . Cellular and molecular basis of portal hypertension. Clin Liver Dis. 2001; 5(3):629-44. DOI: 10.1016/s1089-3261(05)70185-9. View

Sansoe G, Aragno M, Mastrocola R, Restivo F, Mengozzi G, Smedile A . Neutral endopeptidase (EC 3.4.24.11) in cirrhotic liver: a new target to treat portal hypertension?. J Hepatol. 2005; 43(5):791-8. DOI: 10.1016/j.jhep.2005.04.017. View

Lubel J, Herath C, Burrell L, Angus P . Liver disease and the renin-angiotensin system: recent discoveries and clinical implications. J Gastroenterol Hepatol. 2008; 23(9):1327-38. PMC: 7166336. DOI: 10.1111/j.1440-1746.2008.05461.x. View

Lubel J, Angus P . Modern management of portal hypertension. Intern Med J. 2005; 35(1):45-9. DOI: 10.1111/j.1445-5994.2004.00739.x. View

Tamargo Menendez J . The Mechanism of Action of LCZ696. Card Fail Rev. 2017; 2(1):40-46. PMC: 5491035. DOI: 10.15420/cfr.2016:1:1. View

Liczek M, Panek I, Damianski P, Jeczen O, Jazwiec J, Kuna P . Neprilysin inhibitors as a new approach in the treatment of right heart failure in the course of chronic obstructive pulmonary disease. Adv Respir Med. 2018; . DOI: 10.5603/ARM.a2018.0028. View

Tandon P, Abraldes J, Berzigotti A, Garcia-Pagan J, Bosch J . Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis. J Hepatol. 2010; 53(2):273-82. DOI: 10.1016/j.jhep.2010.03.013. View

Kusaka H, Sueta D, Koibuchi N, Hasegawa Y, Nakagawa T, Lin B . LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone. Am J Hypertens. 2015; 28(12):1409-17. DOI: 10.1093/ajh/hpv015. View

10.

Reichen J, Gerbes A, Steiner M, Sagesser H, Clozel M . The effect of endothelin and its antagonist Bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver. J Hepatol. 1998; 28(6):1020-30. DOI: 10.1016/s0168-8278(98)80352-8. View

11.

Moreau R, Tazi K, Komeichi H, Pussard E, Lebrec D . Haemodynamic responses to a ring-deleted analogue of atrial natriuretic peptide in rats with cirrhosis. Liver. 2000; 20(1):88-92. DOI: 10.1034/j.1600-0676.2000.020001088.x. View

12.

Abraldes J, Iwakiri Y, Loureiro-Silva M, Haq O, Sessa W, Groszmann R . Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. Am J Physiol Gastrointest Liver Physiol. 2006; 290(5):G980-7. DOI: 10.1152/ajpgi.00336.2005. View

13.

Huang H, Wang S, Chan C, Lee F, Chang F, Lin H . Chronic inhibition of nitric oxide increases the collateral vascular responsiveness to vasopressin in portal hypertensive rats. J Hepatol. 2004; 40(2):234-8. DOI: 10.1016/j.jhep.2003.10.010. View

14.

Levin E, Gardner D, Samson W . Natriuretic peptides. N Engl J Med. 1998; 339(5):321-8. DOI: 10.1056/NEJM199807303390507. View

15.

Clemmesen J, Giraldi A, Ott P, Dalhoff K, Hansen B, Larsen F . Sildenafil does not influence hepatic venous pressure gradient in patients with cirrhosis. World J Gastroenterol. 2008; 14(40):6208-12. PMC: 2761583. DOI: 10.3748/wjg.14.6208. View

16.

Chang C, Lee W, Huang H, Lee F, Wang S, Lin H . Aliskiren reduces portal pressure in portal hypertensive rats. Eur J Clin Invest. 2011; 42(5):526-33. DOI: 10.1111/j.1365-2362.2011.02611.x. View

17.

Roksnoer L, Van Veghel R, de Vries R, Garrelds I, Bhaggoe U, Friesema E . Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats. Kidney Int. 2015; 88(1):109-20. DOI: 10.1038/ki.2015.107. View

18.

Thenappan T, Goel A, Marsboom G, Fang Y, Toth P, Zhang H . A central role for CD68(+) macrophages in hepatopulmonary syndrome. Reversal by macrophage depletion. Am J Respir Crit Care Med. 2010; 183(8):1080-91. PMC: 3086745. DOI: 10.1164/rccm.201008-1303OC. View

19.

Kulmatycki K, Langenickel T, Ng W, Pal P, Zhou W, Lin T . Pharmacokinetics and safety of sacubitril/valsartan (LCZ696) in patients with mild and moderate hepatic impairment . Int J Clin Pharmacol Ther. 2017; 55(9):728-739. DOI: 10.5414/CP202988. View

20.

Ferro C, Spratt J, HAYNES W, Webb D . Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation. 1998; 97(23):2323-30. DOI: 10.1161/01.cir.97.23.2323. View